Form 4 for CRVO CervoMed Inc.
Accepted 2022-04-19 00:00:00 ET · period of report 2022-04-18 · accession 0001437749-22-009234 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-19 | 2022-04-18 | CRVO | Cobuzzi Robert Joseph Jr. | Pres, CEO, Dir | C - Cnv Deriv | $25.00 | +100 | 792 | +14% | +$2,500 |
| D | 2022-04-19 | 2022-04-18 | CRVO | Cobuzzi Robert Joseph Jr. | Pres, CEO, Dir | C - Cnv Deriv | $25.00 | -100 | 0 | -100% | -$2,500 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-18 | C | A | 100 | $25.00 | 792 | D | — | — | (F2) All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022. (F1) As previously announced, on March 18, 2022, the Reporting Person purchased 100 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Shares"), from the Issuer at a purchase price of $25.00 per Series C Share in a private placement. On April 18, 2022, in accordance with Section 8(a) of the Certificate of Designation of Preferences, Rights, and Limitations of the Series C Convertible Preferred Stock (the "Certificate of Designation"), the Issuer delivered to the Reporting Person written notice of the Mandatory Conversion (as defined in the Certificate of Designations) of all outstanding Series C Shares into an equivalent number of shares of the Company's common stock, par value $0.001, pursuant to and in accordance with the terms of the Certificate of Designation. |
| 2 | Derivative | Series C Convertible Preferred Stock | 2022-04-18 | C | D | 100 | $25.00 | 0 | D | $25.00 · — to — | 100 Common Stock | (F1) As previously announced, on March 18, 2022, the Reporting Person purchased 100 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Shares"), from the Issuer at a purchase price of $25.00 per Series C Share in a private placement. On April 18, 2022, in accordance with Section 8(a) of the Certificate of Designation of Preferences, Rights, and Limitations of the Series C Convertible Preferred Stock (the "Certificate of Designation"), the Issuer delivered to the Reporting Person written notice of the Mandatory Conversion (as defined in the Certificate of Designations) of all outstanding Series C Shares into an equivalent number of shares of the Company's common stock, par value $0.001, pursuant to and in accordance with the terms of the Certificate of Designation. (F2) All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022. |